Italia markets close in 1 hour 46 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
18,47+0,66 (+3,71%)
Al 09:44AM EST. Mercato aperto.
Accedi per pubblicare un messaggio.
  • i
    iamaverb
    $EDIT conversation
    Over the past 3 months, I have divested myself from the market, including half of my $BEAM, 90% of $EDIT, and most of LCID. Everything else is gone, as I believe the bottom isn't near. FYJB and your singular attention to everything that doesn't matter.
  • S
    Short Legend
    $EDIT conversation
    Johnson_Navin.R2 months ago
    $EDIT conversation
    Today may be the last time to buy Editas below $40.
  • M
    MickTheAwesome
    Market observation:

    It seems growth stocks and in particular biotech (CRISPR) has a little more correction to run its course. Don’t even want to guess when it will stop but it’s not indefinite. $NTLA - $BEAM - $CRSP will fare better and might even slightly rise while $CRBU looks to have hit stable life support. Hamstrung by the Broad $EDIT looks likely to hit the teens and could possibly be an attractive buy around $15 -$20 if management produce a coherent road map and negotiate new tech from the Broad to start a new pipeline. So if you haven’t spent all your powder buying these false dips keep an open eye (pun intended) on Editas.
  • i
    iamaverb
    $EDIT conversation
    Call me a gambler but I just bought $BEAM & $EDIT DEC 17 Calls to get us through ASH, where Liu has a 45-minute presentation.
  • i
    iamaverb
    $BEAM conversation
    The FDA approved the IND for $BEAM -101 to begin dosing for sickle cell disease on November 8th of this year, while Editas received their IND approval for $EDIT -301, a sickle cell treatment on January 11th of this year. Neither company has commenced dosing, and I can only hope Beam doesn't take as long to begin their dosing as Editas has.
  • J
    Johnson_Navin.R
    $BEAM conversation
    Like I've said before, one step forward, two steps back.
    $BEAM $EDIT
  • V
    VirginiaLova
    $CRSP conversation
    In January 2021, Editas’ IND was accepted by the FDA. NOVEMBER 2021 Editas earnings update included the following:

    “EDIT-301 for Sickle Cell Disease
    Enrolling patients for initial dosing
    … The Phase 1/2 RUBY trial for the treatment of sickle cell disease is currently enrolling study participants and expects to begin dosing in the first half of 2022”

    $BEAM IND is nice but realistically looking at 2023 -2024 for a first data cut from $Beam or $Edit.

    Crsp partnership with $Vrtx looks more and more and more brilliant every day.
  • S
    Short Legend
    $CRSP conversation
    You do realise it was all hype and the smart money has transitioned over to EV and renewable energy for the rest of the year following the passing of the infrastructure bill? Please tell me you realise that.

    $EDIT
  • i
    iamaverb
    $EDIT conversation
    I wrote this 24 days ago and was pounce upon by Mick for spreading fear. It appears to have come true today and is apparently shows up as pattern at Editas. EX-CEO Bosley infamously began the pattern years ago.
    iamaverb25 days ago
    $EDIT conversation
    Charlie, say it ain't so. The last time we had upper management sell so many shares in such a short amount of time that person was shown the door soon after. Ok, I get it, you received 225,000 stock options in 09.09.2016 which vested equally over the next 4 years, but why are you dumping this latest 25% of those shares so quickly?

    The company seams a little devious to me this morning by trying to bury Charlie's story with two additional pr's just minutes after his notice of departure. BTW, the company did release a new January presentation this morning also.
  • O
    Offer
    $CRSP conversation
    We should actually be happy about this market correction. Just imagine, if all the big 4 were trading at their highs now, what would we have thought to ourselves?
    Two things:
    1) These companies are the future. They will each be worth XXX (Fill in the blank according to your point of view).
    2) I wish I could have bought more at half the price.

    Well, guess what. These companies are still the future. Nothing in their story changed. And we got our chance to buy more shares in prices we thought we will never see again.

    Look at the glass half full.

    $EDIT $BEAM $NTLA $CRSP
  • O
    Offer
    $EDIT conversation
    We would like to welcome you on board on our flight to 100B valuation, we know you had other choices and we thank you for choosing the CRISPR Sector. Flight EDIT has a technical problem with the engine and will depart as soon as there is a new CSO.

    Special thanks go to our investors who are collecting dollars on this flight. Thanks again and see you at the destination.
    $EDIT $NTLA $CRSP $BEAM
  • i
    iamaverb
    $EDIT conversation
    CVC recently filed a motion for summary judgement to get Editas patents nullified in the Interference because certain inventors were left off of the original Cas-9 patents, which was the basis for the EU decision and filed for the court not to allow Editas to amend the patents.
    Broad filed a motion yesterday to add Dr. Luciano Marraffini to the original patents.

    "Broad requested authorization to file a responsive motion contingent on the grant of CVC Substantive Motion 3 for judgment under 35 U.S.C. § 102(f) that the
    involved Broad patents and application name the wrong inventors"
    by leaving Dr. Luciano Marraffini off of the patents.

    The PTAB decision
    "Accordingly, it is ORDERED that Broad is authorized to file a motion
    seeking to change the named inventors on its involved patents and application."

    CVC also wants to subpoena Marraffini and a Dr. Shuailiang Lin who might cast doubt on who invented first, but neither party wants to testify for CVC, and Broad is preparing their motion to quash the request.

    These proceedings are a game of chess

    $EDIT $CRSP
  • V
    VirginiaLova
    $CRSP conversation
    Crispr Therapeutics initiated with a Buy at SunTrust SunTrust CRSP
    Crispr Therapeutics initiated with a Buy at SunTrust SunTrust CRSP
    thefly.com
  • i
    iamaverb
    $EDIT conversation
    @Kenneth/Vara. It is mysterious but the numbers are coming from NASDAQ. They show 3 trades alone of 1,596,773 shares at 16:39:15, 16:57:46, and 17:09:22, with one of the trades cancelled at 16:54:57. These are of course among many other large trades at the end of the day. One possible explanation is the market makers have a deal with the large institutions to hold large numbers of shares in their accounts and then trade them after hours allowing the tutes' to unwind their short positions near or at at the session highs, instead of them having to cover their short positions on the open market which would normally drive the share price much higher. Regardless, something exciting is going on with $EDIT and $NTLA, which had 10x's the normal volume today.
    Does anyone care to speculate? One common denominator is the recent patent interference review, or is it just the end of the quarter house cleaning with the institutional holders?
  • S
    Sean
    $EDIT conversation
    I remember a conversation with iamaverb some time ago. Here is a part of it:

    • iamaverb
    2 months ago
    $EDIT conversation
    I'm not advocating anyone do anything, but I sold 4,000 shares of ADVM at the close today, roughly half of my holdings, because I feel there may be a stock offering coming in the near future. The company last offered 60 million dollars of shares 1.5 years ago at $6.75 a share so this may be a good time for the company to take advantage of current market conditions. Regardless, I am keeping my powder dry by selling today and positioning my oil stocks for sale if and when Editas makes an announcement and replicates the recent rise in ADVM share price. US oil stockpiles fell by 9.5 million barrels last week and oil jumped 4.39% today so the trend is my friend. Could this be the perfect storm out on the horizon?
    Less
    ReplyReplies (14)
    4

    iamaverb
    2 months agoReplied to a reaction
    $EDIT conversation
    Sean thanks for recognizing the point as to why I bring up ADVM on this board. I expect even more spectacular gains once Editas actually shows the market they are players in the CRISPR game.
    Reply
    21
    A few posts later he says he sold the rest.

    Iamaverb…sometimes you should not even make eye contact
  • J
    J.R. Jackson
    $EDIT conversation
    When the Company reveals reclaimed vision in patients, $EDIT stock price. . . off the charts!
  • k
    kirdes
    $EDIT conversation
    $EDIT 2019-10-10 13G Sumitomo Mitsui Trust Holdings, Inc. bought 4,958,593 mil shares ...is 10% Edit company

    Nikko asset management Inc. bought 5 000 000 mil shares 2019-10-09 this is 10% EDIT company

    Two japan company bought 20% EDIT
  • A
    Anonymous Green
    $CRSP conversation
    Today CRSP had a good day even if it may not seem like it. What I'm seeing after the run-up all CRISPR stocks experienced is consolidation. The daily chart of $EDIT shows there's appetite to stay on these levels and move up from here. Same could be said of $NTLA and $BEAM. Imo, in the near future further consolidation will happen around the $70 level and if the macro stays good the race for second place to break $100 is on. Who will it be EDIT, NTLA or BEAM...
  • B
    Bill
    $CRSP conversation
    $BLUE uses an entirely different technology when compared to $BEAM, $CRSP, $EDIT and $NTLA. $BLUE was using a gene therapy that was much older and less precise. Today you can pick up bargins in gene editing stocks. Good luck to everyone. https://www.youtube.com/watch?v=3pcYlTR_mh8 . The underlying gene editing technologies used by $BEAM, $CRSP, $EDIT and $NTLA is still sound.
    Bluebird bio Temporarily Suspends Phase 1/2 and Phase 3 Studies of Lentiglobin Gene Therapy for SCD
    www.youtube.com